Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Understand the source comparison

Clinical Evidence vs Marketing Claims: What Studies Actually Show

Here's the blunt reality: peptides help with cognitive enhancement in animal models and small human trials—but the dosing protocols, administration routes, and outcome measures used in research rarely match the products marketed online. Cerebrolysin has 50+ pu

No winner is assigned.

This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.

  • Here's the blunt reality: peptides help with cognitive enhancement in animal models and small human trials—but the dosing protocols, administration routes, and outcome measures used in research rarely match the products marketed online. Cerebrolysin has 50+ published trials spanning stroke recovery, traumatic brain injury, and age-related cognitive decline—most using IV infusion at 30–60mL daily for 10–21 days. A 2015 Cochrane review analyzing 6 randomized controlled trials (1,501 total participants) found moderate-quality evidence for improved cognition in vascular dementia, measured via ADAS-cog and MMSE scores.
  • That's clinical-grade evidence. Compare that to synthetic peptides sold as 'research chemicals' with dosing recommendations derived from Reddit anecdotes rather than pharmacokinetic data. Dihexa, for example, shows profound cognitive effects in rodent models at 0.1mg/kg—but human equivalent dosing, accounting for metabolic scaling, hasn't been established through Phase I trials. The compound remains unscheduled and legal for research use, but claims about human cognitive enhancement extrapolate from preclinical data without clinical validation.
  • MK-677 (ibutamoren) illustrates the evidence gap clearly. It's a ghrelin mimetic that increases growth hormone and IGF-1 secretion—hormones with documented roles in hippocampal neurogenesis. A 2008 study in Journal of Clinical Endocrinology & Metabolism showed MK-677 increased IGF-1 by 60% in elderly adults over 12 months, but cognitive testing (digit span, verbal fluency, trail-making) showed no significant improvement compared to placebo. Mechanism doesn't guarantee outcome.
  • P21 shows promise but remains in early-stage research. The 2013 Aging Cell paper documented memory retention improvements in aged mice, but no human trials exist as of 2026. When researchers write 'these findings suggest potential therapeutic application,' that's scientific code for 'we have preliminary data, not clinical proof.'
  • Cerebrolysin
  • Receptor-mediated transcytosis (low MW peptides)
  • BDNF upregulation, anti-apoptotic signaling
  • 50+ RCTs in stroke, dementia, TBI—moderate evidence for cognitive improvement
  • 30–60mL IV daily × 10–21 days
  • Strongest clinical evidence base; dosing requires medical supervision
  • Dihexa
  • Lipophilic modification (oral bioavailable)
  • HGF/c-Met activation, synaptogenesis
  • No human trials; preclinical only
  • 0.1mg/kg in rodent studies
  • Potent mechanism, zero human safety data; extrapolation from animal models unreliable
  • P21
  • Intranasal delivery bypassing BBB
  • NMDA receptor modulation, CREB pathway
  • No human trials; rodent studies only
  • 1–3mg intranasal in rodent studies
  • Promising memory retention effects in aged mice; human dosing unknown
  • MK-677
  • Small-molecule, passive diffusion
  • GH/IGF-1 secretion, indirect neurogenesis
  • Multiple Phase II trials; no cognitive benefit vs placebo
  • 25mg oral daily
  • Increases IGF-1 reliably, but cognitive outcomes don't follow—mechanism ≠ efficacy
  • Thymalin
  • Unclear (peptide mixture)
  • Antioxidant, immune modulation
  • Limited human data outside Eastern Europe
  • 10mg IM daily × 10 days
  • Neuroprotective rationale plausible; clinical evidence for cognition weak

Related resources

More comparisons